Brief: Biocartis Publishes New Study On Idylla GeneFusion Assay

Biocartis NV

04/05/2022 06:03

May 4 (Reuters) - BIOCARTIS GROUP NV  BCART.BR :
    * PRESS RELEASE BIOCARTIS GROUP NV: NEW STUDY LED BY
MEMORIAL
SLOAN KETTERING CANCER CENTER (NY, US) SHOWS IDYLLA™ GENEFUSION
ASSAY ENABLES MORE RAPID SCREENING OF TARGETABLE FUSIONS
COMPARED TO ROUTINE METHODS
    * THERAPEUTICALLY ACTIONABLE GENE FUSIONS DRIVE
APPROXIMATELY 10%
OF NON-SMALL-CELL LUNG CANCERS
    * CURRENT MOLECULAR METHODS INCLUDING NEXT GENERATION
SEQUENCING
(NGS) ARE COMPLEX WITH LONG TURNAROUND TIMES
    * STUDY(2) DEMONSTRATES IDYLLA™ GENEFUSION ASSAY (RUO(3))
ENABLES
MORE RAPID SCREENING OF TARGETABLE FUSIONS COMPARED TO ROUTINE
METHODS

Source text for Eikon:  ID:nGNE183w7h 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))